124 related articles for article (PubMed ID: 37327667)
1. Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: A global perspective.
Matorras R; Chaudhari VS; Roeder C; Schwarze JE; Bühler K; Hwang K; Chang-Woo C; Iniesta S; D'Hooghe T; Mathur R
Best Pract Res Clin Obstet Gynaecol; 2023 Jul; 89():102349. PubMed ID: 37327667
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.
Bühler KF; Fischer R; Verpillat P; Allignol A; Guedes S; Boutmy E; Bilger W; Richter E; D'Hooghe T
Reprod Biol Endocrinol; 2021 Jun; 19(1):90. PubMed ID: 34134695
[TBL] [Abstract][Full Text] [Related]
3. Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.
Schwarze JE; Venetis C; Iniesta S; Falla E; Lukyanov V; de Agustin Calvo E; D Hooghe T; Roeder C; Matorras R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):203-216. PubMed ID: 35227619
[TBL] [Abstract][Full Text] [Related]
4. The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.
Yang C; Dong N; Li F; Ji Y; Pan Y; She H
J Ovarian Res; 2022 Jun; 15(1):74. PubMed ID: 35729654
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
6. Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study.
Gerber RS; Fazzari M; Kappy M; Cohen A; Galperin S; Lieman H; Jindal S; Buyuk E
Fertil Steril; 2020 Dec; 114(6):1225-1231. PubMed ID: 33012553
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.
Bühler K; Roeder C; Schwarze JE; Lispi M; Allignol A; Falla E; Lukyanov V; D Hooghe T; Fischer R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):188-202. PubMed ID: 35304097
[TBL] [Abstract][Full Text] [Related]
8. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
[TBL] [Abstract][Full Text] [Related]
10. Costs of achieving live birth from assisted reproductive technology: a comparison of sequential single and double embryo transfer approaches.
Crawford S; Boulet SL; Mneimneh AS; Perkins KM; Jamieson DJ; Zhang Y; Kissin DM
Fertil Steril; 2016 Feb; 105(2):444-50. PubMed ID: 26604068
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands.
Fragoulakis V; Pescott CP; Smeenk JM; van Santbrink EJ; Oosterhuis GJ; Broekmans FJ; Maniadakis N
Appl Health Econ Health Policy; 2016 Dec; 14(6):719-727. PubMed ID: 27581117
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor priming improves embryos and pregnancy rate in patients with poor ovarian reserve: a randomized controlled trial.
Jinno M; Tamaoka Y; Teruya K; Watanabe A; Hatakeyama N; Goda T; Kimata H; Jinno Y
Reprod Biol Endocrinol; 2023 Mar; 21(1):29. PubMed ID: 36944952
[TBL] [Abstract][Full Text] [Related]
13. In vitro fertilization and multiple pregnancies: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(18):1-63. PubMed ID: 23074488
[TBL] [Abstract][Full Text] [Related]
14. Cryopreserved oocyte versus fresh oocyte assisted reproductive technology cycles, United States, 2013.
Crawford S; Boulet SL; Kawwass JF; Jamieson DJ; Kissin DM
Fertil Steril; 2017 Jan; 107(1):110-118. PubMed ID: 27842997
[TBL] [Abstract][Full Text] [Related]
15. The number of oocytes associated with maximum cumulative live birth rates per aspiration depends on female age: a population study of 221 221 treatment cycles.
Law YJ; Zhang N; Venetis CA; Chambers GM; Harris K
Hum Reprod; 2019 Sep; 34(9):1778-1787. PubMed ID: 31398253
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial.
Boostanfar R; Gates D; Guan Y; Gordon K; McCrary Sisk C; Stegmann BJ
Fertil Steril; 2016 Aug; 106(2):300-305.e5. PubMed ID: 27090863
[TBL] [Abstract][Full Text] [Related]
17. A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study.
Choi BC; Zhou C; Ye H; Sun Y; Zhong Y; Gong F; Sini I; Abramova N; Longobardi S; Hickey M; D'Hooghe T
Reprod Biol Endocrinol; 2022 Jan; 20(1):15. PubMed ID: 35039049
[TBL] [Abstract][Full Text] [Related]
18. Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.
Orvieto R; Venetis CA; Fatemi HM; D'Hooghe T; Fischer R; Koloda Y; Horton M; Grynberg M; Longobardi S; Esteves SC; Sunkara SK; Li Y; Alviggi C
Front Endocrinol (Lausanne); 2021; 12():675670. PubMed ID: 34040586
[TBL] [Abstract][Full Text] [Related]
19. A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.
Lehert P; Arvis P; Avril C; Massin N; Parinaud J; Porcu G; Rongières C; Sagot P; Wainer R; D'Hooghe T
Hum Reprod; 2021 May; 36(6):1600-1610. PubMed ID: 33860313
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS).
Grynberg M; Cedrin-Durnerin I; Raguideau F; Herquelot E; Luciani L; Porte F; Verpillat P; Helwig C; Schwarze JE; Paillet S; Castello-Bridoux C; D'Hooghe T; Benchaïb M
Best Pract Res Clin Obstet Gynaecol; 2023 Jun; 88():102308. PubMed ID: 36707343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
